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 24 
ABSTRACT 25 
Objective: Effective interventions of future health-care require a better understanding of the health risks associated with early onset of 26 
menopause and diabetes, but the necessary data are scarce. Little quantitative information is available about the combined association 27 
of early menopause and diabetes on life expectancy and the number of years lived with and without diabetes.  28 
Methods: We included 3,650 postmenopausal women aged 45+ years from the Rotterdam Study, a prospective population-based 29 
cohort study. Age at menopause categories were defined as: early (≤44 years old), normal (45-54 years old) and late (≥55 years old). 30 
For life table calculations, we used prevalence, incidence rates and hazard ratios for three transitions (free of diabetes to diabetes, free 31 
of diabetes to death and diabetes to death) stratifying by age at menopause categories and adjusting for confounders. 32 
Results: Compared to late menopause, the difference in life expectancy for women who experienced early menopause was -3.5 33 
95%CI: -6.6,-0.8 years overall and -4.6 95%CI: -8.9,-0.9 years without diabetes. Compared to age at normal menopause, the 34 
difference in life expectancy for women who experienced early menopause was -3.1 95%CI: -5.1,-1.1 years overall and -3.3 95%CI: -35 
6.0,-0.6 years without diabetes.  36 
Published in final edited form as: Menopause. 2019 Apr;26(4):387-394. doi: 10.1097/GME.0000000000001246. 
4 
 
Conclusions: Women who experienced early menopause lived less long and spent fewer years without diabetes than women who 37 
experienced normal or late menopause. 38 
Keywords: Age at menopause; life expectancy; type 2 diabetes  39 
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ABBREVIATIONS  40 
T2D, Type 2 diabetes 41 
RS, The Rotterdam Study 42 
LE, Life expectancy 43 
HR, Hazard Ratio 44 
CI, Confidence Interval 45 
IQR, Interquartile range 46 
SD, Standard deviation 47 
VIF, Variance inflation factor  48 
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INTRODUCTION 49 
Diabetes is one of the major causes of premature illness and death in most countries and imposes a substantial financial burden to 50 
society, especially in women [1, 2]. Almost 1 in 2 women will develop type 2 diabetes (T2D) during their lifetime, and recent data has 51 
shown that the age-standardised prevalence of diabetes among adult women has increased in the past 30 years from 5.0% to 7.9% [3, 52 
4]. 53 
In women, T2D often manifests during mid-life and thus coincides with the timing of the menopausal transition [5]. Emerging 54 
evidence shows an association between age at menopause and diabetes with studies reporting almost a 2-fold increased risk of T2D 55 
with early onset of menopause [6, 7]. Also, it is well established that early onset of menopause is associated with early death[8-10]. 56 
This could be important because, while mortality rates for women with non-T2D have declined over time [11], mortality rates for 57 
women with T2D may have instead increased [11]. 58 
Effective interventions and accurate projections of future health-care costs require a better understanding of the health risks associated 59 
with early onset of menopause, but the relevant data are scarce. To our knowledge, no study up to date has quantified (calculating the 60 
number of years lived with and without diabetes) the combined association of early menopause and T2D with life expectancy. 61 
Previous estimates reflecting the association of age at menopause with diabetes have been limited to absolute risks or lifetime risk 62 
without combining information about the number of the remaining years lived with or without diabetes, raising a gap in the intuitive 63 
understanding of risk and impact communicated among doctors and patients [6, 7, 12].  64 
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Two studies have examined the association of age at menopause with total life expectancy [13, 14]. Ossewaarde and colleagues, in a 65 
breast cancer-screening cohort, reported that both premature and early onset of menopause were associated with a decrease in life 66 
expectancy of approximately 1 to 2 years [13]. Snowdon et al. concluded that each-one year decrease in age at menopause was 67 
associated with a 0.47-year decrease in the age at death in women with natural menopause before the age of 47 years [14]. However, 68 
these studies did not distinguish between life expectancy with and without diabetes and did not provide a direct observation of a well-69 
defined population, as the results were obtained through modelling and simulation using nation-wide mortality data.  70 
In a large population of postmenopausal women, we aimed to calculate and compare the association of age at natural menopause with 71 
total life expectancy and the number of years lived with and without T2D.  72 
 73 
METHODS 74 
Population for analyses 75 
The Rotterdam Study (RS) is a population-based prospective cohort study of individuals aged 45years and over, living in Rotterdam, 76 
the Netherlands. The rationale and design of the RS have been previously described [15].  77 
The present study used data from the third visit of the first cohort, RSI-3 (March 1997- December 1999) and the baseline examinations 78 
of the second, RSII-1 (February 2000-December 2001) and third cohort, RSIII-1 (February 2006-December 2008). Information about 79 
the visits and participants used for this study are presented in Supplemental Digital Content Figure S1. A total of 6816 women were 80 
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eligible for the analysis. Women who were not postmenopausal (N=741), had missing information on age of menopause (N=145), 81 
experienced non-natural (N=1408) or unknown type of menopause (N=20) were excluded from the analyses. Furthermore, we 82 
excluded 434 women who reported using oral contraceptives during the menopause transition, since these may mask or influence the 83 
onset of menopause [16] and are associated with an increased risk of T2D in postmenopausal women [17]. The remaining 3650 84 
postmenopausal women were eligible for the analyses (Figure 1). 85 
Study population 86 
The Rotterdam Study (RS) is a population-based prospective cohort study ongoing since 1990 in the city of Rotterdam in The 87 
Netherlands. Potential participants aged 55 years and over were invited in random clusters. Names and addresses were drawn from the 88 
municipal register which is reliable, complete and up to date. The baseline cohort (RSI) included 7983 participants (78% of 10,215 89 
invitees)[18]. Over the years, two more rounds were held. The first, in 2000–2001, included all inhabitants aged 55 years and over, 90 
recruiting 3011 participants (out of 4472 invitees) (RSII)[18]. The second extension initiated in 2006, included 3932 participants aged 91 
45 years and over, out of 6057 invited (RSIII)[18]. Detailed information about the visits and participants of the Rotterdam study are 92 
presented in Supplemental Digital Content Figure S1. The overall response figure for all three cycles was 72.0% (14,926 of 20,744). 93 
RS complies with the Declaration of Helsinki and has been approved by the Medical Ethics Committee of the Erasmus Medical Centre 94 
and complies with the Dutch Ministry of Health, Welfare and Sport. All participants provided written informed consent to obtain and 95 
process data from their treating healthcare providers. 96 
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Assessment of age at menopause 97 
The self-reported age at menopause was assessed during the baseline interview using a questionnaire. Age at menopause was defined 98 
in retrospect as the age at final menstrual period, which was followed by cessation of menses that lasted at least 12 months [19]. In 99 
addition, to define the nature of menopause, women were asked to report if bleeding was ceased naturally or was ceased because of 100 
other reason. For all women reporting menopause after gynecologic surgery or radiation therapy and for those reporting any other 101 
operations that might have led to menopause, information on the exact date and type of operation was verified using general 102 
practitioners' records. 103 
Ascertainment of type 2 diabetes 104 
The participants were followed from the date of baseline center visit onwards. Cases of T2D were ascertained at baseline and during 105 
follow-up through: (i) active follow-up using general practitioners’ records, (ii) hospital discharge letters and (iii) glucose 106 
measurements from RS visits that took place approximately every 4 years [20]. T2D was defined according to recent WHO guidelines, 107 
as a fasting blood glucose ≥ 7.0 mmol/L, a non-fasting blood glucose ≥ 11.1 mmol/L (when fasting samples were absent), or the use of 108 
glucose-lowering medication. Information regarding the use of glucose-lowering medication was derived from both structured home 109 
interviews and linkage to pharmacy records [20]. Two study physicians independently adjudicated all potential events of T2D. In case 110 
of disagreement, consensus was sought with an endocrinologist. Follow-up data were through January 1st 2012. 111 
Follow-up for mortality 112 
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Mortality data were obtained by notification from the municipal administration. Participants were followed from the first day they 113 
entered the study till the day of death, the day of lost to follow-up or the last date of contact, whichever came first. Data on all-cause 114 
mortality and living status were updated biweekly until August 1st 2016. The method applied requires all outcomes to have the same 115 
end date. In our data, the follow up for diabetes was until January 1st 2012, therefore all the analyses were truncated accordingly. 116 
Assessment of potential confounders  117 
Based on previous literature[7, 10, 16, 17, 21-24], biological plausibility and data availability in the RS, potential confounding 118 
variables (including age, smoking, alcohol, education level, hormone therapy, physical activity, age at menarche, number of 119 
pregnancies and oral contraceptive use) were selected for the analyses. Also, to account for any potential effect of the cohorts in the 120 
RS, we additionally adjusted all our analyses for cohort (I, II and III). Information on current health status, medical history, medication 121 
use and smoking behavior was obtained at baseline (RSI-3, RSII-1 and RSIII-1). Participants were asked whether they were currently 122 
smoking cigarettes, cigars, or pipes. Alcohol intake was assessed in grams of ethanol per day. Education was defined according to the 123 
standard international classification of education as low (primary education), intermediate (secondary general or vocational 124 
education), or high (higher vocational education or university). Data on age at menarche were collected by asking women, “How old 125 
were you when you had your first menstrual period?”. The retrospective data on self-reported number of pregnancies and use of 126 
hormone therapy were collected by a questionnaire during the home interview. Physical activity was assessed using the LASA 127 
Physical Activity Questionnaire (LAPAQ) and is expressed in METhours/week. 128 
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Data analysis 129 
Data are presented as mean (± SD) for normally distributed continuous variables and median (range) for continuous variables that are 130 
not normally distributed. When fitting the models and checking for multicollinearity, in our analyses variance inflation factor (VIF) 131 
was lower than 3, suggesting no evidence of collinearity.  The One-way ANOVA test (for continuous variables) and χ2 (for 132 
categorical variables) were used to compare parameters between the groups. We created population-based multistate life tables to 133 
calculate life expectancy and years lived with and without T2D in early (≤44 years old), normal (45-54 years old) and late menopause 134 
(≥55 years old, reference) categories. The multistate life table is a demographic tool that allows the experience of individuals in 135 
different health states to be combined in order to calculate the total life expectancy and the amount of years that individuals could 136 
expect to live in the different health states. We considered 3 different health states: free of T2D, T2D, and death. Participants could 137 
experience the following transitions: from free of T2D to T2D or death and from T2D to death. No backflows were allowed (eg. from 138 
having T2D to not having T2D), and only the first entry into a state was considered. 139 
To obtain transition rates, we first calculated the overall age-specific rates for each transition. Next, we calculated the prevalence of 140 
early, normal, and late menopause by 10-year age groups, and separately for women with and without diabetes. Hazard ratios (HRs) 141 
comparing women who experienced early and normal menopause to women who experienced late menopause were calculated using 142 
Poisson regression (“Gompertz” distribution) in two models. In model 1 we adjusted for age and cohort. In model 2 we additionally 143 
adjusted for potential confounders including: smoking status (current smokers vs former/ever smokers), alcohol intake (continuous), 144 
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education level (low, intermediate and high), physical activity (continuous), use of oral contraceptives (yes vs. no), use of hormone 145 
therapy, and reproductive factors (age at menarche and number of pregnancies of at least 6 months). Finally, we calculated three sets 146 
of transition rates for each menopausal age category using (i) the overall transition rates, (ii) the adjusted HRs for T2D and mortality, 147 
and (iii) the prevalence of age at natural menopause categories by presence of T2D. Similar calculations have been described 148 
previously [25, 26]. Considering the age range of participants in RS and the small number of participants between 45 to 50 years old 149 
(N=34) we a priori decided to start the multistate life tables at the age of 50 years.  We used Monte Carlo simulation (parametric 150 
bootstrapping) with 10,000 runs to calculate the 95 % confidence intervals of our life expectancy estimates with @RISK software 151 
(Palisade Corporation, Ithaca, New York) runs [27]. To deal with missing values, we used multiple imputation in SPSS (IBM SPSS 152 
Statistical for Windows, Armonk, New York: IBM). To calculate the HRs and the transition rates we used STATA version 12 for 153 
Windows (StataCorp, College Station, Texas). 154 
Sensitivity analyses 155 
Several sensitivity analyses were performed. To examine the impact of women who reported use of oral contraceptive at onset of 156 
menopause, we included them in the analyses (n=434). Also, to investigate both, the association of natural and non-natural menopause 157 
with T2D risk and life expectancy, we included in the analyses women with non-natural menopause. Furthermore, to explore whether 158 
there were significant differences between early and normal age at menopause in risk of T2D and mortality, life expectancy, and years 159 
lived with and without T2D, we repeated the analysis using normal age at menopause category as reference. 160 
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RESULTS 161 
Baseline characteristics 162 
Mean age at menopause in the early, normal and late categories were respectively 41years (SD = 3.0), 50 years (SD=2.5) and 56 years 163 
(SD=1.6) (Table 1). Compared to women who experienced late menopause, early menopausal women had lower education levels, 164 
drank less and were more likely to smoke (Table 1). 165 
Diabetes events and death 166 
Of the 3240 postmenopausal women free of diabetes at baseline, 305 women developed incident T2D over a median follow-up of 9.2 167 
years (Table 2). Among women free of diabetes, 489 women died during the follow-up (median= 6.9 years), whereas 164 women died 168 
among women with T2D (median follow-up= 4.9 years). Both models yielded similar estimates; therefore, we further report the 169 
results of the most adjusted model (model 2). Compared to late menopause, early (HR=1.42, 95% CI: 1.01, 2.00), but not age at 170 
normal menopause (HR=1.13, 95% CI: 0.85, 1.49) was associated with an increased risk of mortality among women free of diabetes. 171 
Among diabetic women with early and normal menopause, the HRs for mortality were 1.64 95% CI: 0.93, 2.88, and 0.85 95% CI: 172 
0.52, 1.39 respectively, relative to those with late menopause (Table 2). 173 
Total life expectancy and life expectancy with and without type 2 diabetes. 174 
Published in final edited form as: Menopause. 2019 Apr;26(4):387-394. doi: 10.1097/GME.0000000000001246. 
14 
 
The association of early, normal, and late menopause with the risk of each health/disease/death transition was translated into the 175 
number of years lived with and without diabetes (Figure 2). Total life expectancy at the age of 50 years was lower in women who had 176 
an early menopause and higher in women who had a late menopause. Compared to women with late menopause, the difference in life 177 
expectancy for women with normal and early age at menopause was 0.5 95% CI: -2.1, 1.3 and 3.5 95% CI: -6.6,-0.8 years, 178 
respectively. Compared to women with late menopause, the difference in life expectancy for women with normal and early age at 179 
menopause was 1.3 95% CI: -4.3, 0.8 and 4.6 95% CI: -8.9,-0.9 years without T2D as well as 0.8 years 95% CI: -1.3, 2.4 and 1.1 years 180 
95% CI: -1.8, 4.4 years with T2D, respectively. 181 
Sensitivity analyses 182 
Total life expectancy and the number of years lived with and without T2D did not significantly differ after including women who 183 
reported using oral contraceptives.  These results are presented in Supplemental Digital Content Table S1, Table S2, Figure S2. The 184 
results were attenuated, but did not substantially change after the inclusion of women with non-natural menopause (results are shown 185 
in Supplemental Digital Content Table S3, Table S4 and Figure S3). Furthermore, the difference in life expectancy for women who 186 
experienced early menopause, compared to women with normal age at menopause was -3.1 95% CI: -5.1,-1.1) and -3.3 95% CI: -9.5, 187 
-0.6 years overall and without T2D respectively, and 0.2 95% CI: -2.0,2.8 years with T2D, although the latter was not a statistically 188 
significant difference. Results using the normal menopause group as the reference category are presented in Supplemental Digital 189 
Content Figure S2, Table S5 and S6. 190 
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DISCUSSION 191 
At the age of 50 years, women who experienced early menopause lived less years and spent fewer years without diabetes than women 192 
who experienced normal or late menopause. Compared to women with normal or late age at menopause, women with early 193 
menopause lived at least 3.1 years fewer overall and at least 3.3 years fewer without diabetes, respectively. 194 
The decreased life expectancy without diabetes among women with early menopause might be due to the increased risk of T2D and 195 
mortality associated with early menopause. The higher risk of diabetes in women with early age at natural menopause might reflect an 196 
earlier diagnosis of diabetes across the lifespan and therefore, a decreased life expectancy without T2D, although the difference in 197 
years lived overall and without T2D did not differ significantly. Furthermore, early menopause was also associated with an increased 198 
mortality risk among participants without T2D, resulting in a further decrease in total life expectancy and number of years lived 199 
without T2D. The number of years lived with diabetes was a result of incident diabetes risk and mortality risk among those with 200 
diabetes. In our study, no significant association was observed of age at menopause with mortality among women with diabetes, which 201 
could be due to the small number of cases in this transition (transition 3). Life expectancy with diabetes was at least 0.2 and 1.1 years 202 
more for women with early age at menopause compared with those who experienced normal and late menopause respectively. This 203 
reflects two opposing results: 1) higher incidence of diabetes in women who experienced early menopause increasing the time spent 204 
with diabetes; and 2) increased mortality associated with early menopause in diabetic patients, decreasing the time spent with diabetes. 205 
The net result is that women who experienced early menopause lived shorter and did not spend more years with diabetes. 206 
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In our study, total life expectancy in women aged 50 years and over was very similar between normal and late menopause and 207 
significantly decreased in the early menopause group. Consistent with our findings, data from a breast cancer screening cohort 208 
reported that a later menopause is associated with a longer overall survival and higher life expectancy [13]. In that study, women who 209 
experienced menopause at the age of 55 years or after lived 2 and 1 years longer than those who experienced menopause before the 210 
age of 40 and at age 40-44 respectively, which is slightly less than our findings. This discrepancy could be explained by differences in: 211 
(i) age of participants; (ii) categorization of age at menopause and (iii) in the calendar time of baseline measurements. Also, our study 212 
included only women who experienced natural menopause, whereas the previous study included women experiencing natural and not-213 
natural menopause. Furthermore, in the previous study, the calculations for the life tables were made using a hypothetical population 214 
of women aged 50 years, obtaining estimates by modelling and simulation. In contrast, our study calculated the life expectancy with 215 
and without diabetes from direct observation of a well-defined population using multistate life tables. 216 
Previous studies have reported that among major modifiable risk factors, never smoking was associated with the largest gain in total 217 
life expectancy in women (up to 4.1 years), followed by high physical activity (3.4 years) and normal weight (1.0 year) [28]. In our 218 
study, adjustment for these factors to rule out their influence on the association between age at menopause and T2D did not materially 219 
change the results. Previous studies investigating the association of age at menopause and mortality or diabetes, have also reported no 220 
changes in estimates when adjusting for smoking [7, 13], suggesting that smoking habits could not explain our findings. However, it 221 
would be of interest to explore whether smoking and early menopause are related through epigenetic mechanisms which can further 222 
affect women’s health later in life. 223 
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To our knowledge, this is the first study that investigated the association of age at natural menopause with life expectancy with and 224 
without T2D. Other major strengths include the prospective design with a long-term follow-up; the large number of participants and 225 
the adjustments for a broad range of potential confounders.  226 
Several limitations of this study should be addressed. Age at menopause was assessed by questionnaires that could be subject to some 227 
measurement error. Another limitation was the reliance on retrospective self-report of age at menopause that could be subject to 228 
memory and reporting bias, particularly in older women. In addition, inaccuracy from reporting bias would have been non-differential 229 
in relation to the menopausal categories. Hence, it is unlikely that this would have created any difference between groups. However, 230 
because T2D and mortality were assessed prospectively, the subjective measure of age at menopause would likely lead to non-231 
differential misclassification with respect to the outcome, and therefore would likely bias our estimates toward the null. Furthermore, 232 
studies have reported that the validity and reproducibility of self-reported age at menopause is fairly good [8, 29].  233 
Moreover, diabetes might have been subclinical at baseline and because age at menopause was retrospectively self-reported, the 234 
possibility of reverse causality should be considered. However, all women in our study were already postmenopausal years before 235 
incident diabetes occurred. Also, all women in RS had an assessment of fasting plasma glucose which would have helped to detect 236 
subclinical diabetes and therefore reverse causality is less likely to have happened.  237 
Further, a time difference was observed between the start of the RS and the onset of menopause, which might have introduced 238 
immortal-time bias. Nevertheless, if immortal-time bias was present, the true point estimate for the relationship between early 239 
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menopause, T2D and mortality may be larger than we observed. Also, all population-based cohorts involving active participation are 240 
subject to the healthy volunteer effect [30] therefore the mortality rates in our study might be lower than those in the general 241 
population, thus leading to underestimation of the results [31]. Finally, the generalizability of our findings can be limited to middle-242 
aged and older white European populations, and therefore, our results need confirmation in other populations. 243 
These results support findings of prior studies that suggest that age at natural menopause might be a risk factor for mortality. Another 244 
hypothesis might be that both early menopause and premature death could be associated by a third factor, which may also partly 245 
explain the underlying mechanisms of the greater risk of T2D in women with early menopause. Epigenetic modifications such as 246 
DNA methylation of cytosine residues in CpG dinucleotides histone modification and micro RNAs might constitute an additional 247 
pathway linking the timing when menopause occurs with longevity and type 2 diabetes [32]. Future studies should explore epigenetic 248 
modifications associated with age at natural menopause and whether epigenetic signatures can explain the association between the 249 
onset of natural menopause with mortality and type 2 diabetes risk. In addition, our results provide supporting evidence for public 250 
health interventions aiming at delaying in menopause to reduce the incidence of T2D, postpone mortality and prolong total life 251 
expectancy as well as the years lived free of diabetes. Studies have shown that various lifestyle factors [22] such as smoking cessation 252 
[23, 33], low to moderate alcohol consumption [23], better nutrition and lower body mass index [21, 34], better socioeconomic status 253 
[22], are associated with a later menopause. Considering the observational nature of the studies so far, it is unclear whether these 254 
factors have a causal effect on age of menopause. Therefore, more research is needed to understand the direction of these associations 255 
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to help define better health policies. Also, our findings might be important for the health care sector since diabetes poses a significant 256 
financial burden on healthcare and nations’ welfare budget [35]. 257 
CONCLUSIONS 258 
In our study, women who experienced early menopause lived fewer years overall and spent less years without diabetes than women 259 
who experienced normal or late menopause. Future studies are needed to examine the mechanisms behind the association of age at 260 
natural menopause with type 2 diabetes and mortality, in order to tailor prevention and treatment strategies to improve women’s health 261 
across all age-categories of menopause.   262 
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FIGURES 335 
Figure 1. Flow chart of participants in the study, the Rotterdam Study (1997-2012). 336 
Abbreviations: RS the Rotterdam Study 337 
Figure 1 shows the number of women eligible for the analysis after applying the inclusion and exclusion criteria to enter the study. 338 
 339 
Figure 2. Life expectancy at 50 years old among women with late, normal and early menopause. 340 
Abbreviations: LE life expectancy; T2D type 2 diabetes 341 
In dark grey is depicted life expectancy free of diabetes and in light grey is depicted life expectancy with diabetes. 342 
*Results after adjusted for: age, cohort, education levels, alcohol, smoking, age at menarche, hormone therapy, physical activity, 343 
number of pregnancies and oral contraceptive use. 344 
**Late menopause group is the reference category. 345 
  346 
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Figure 1. Flow chart of participants in the study, the Rotterdam Study (1997-2012). 357 
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Table 1. Baseline Characteristics of 3.650 Women by Age at Menopause Categories, the Rotterdam Study (1997-2012). 
 
Categories of age at menopause* 
 
Characteristics Early (n= 414) Normal (n=2787) Late (n= 449) P-value 
Age, mean (SD), y 69.0 (10.6) 67.4 (9.8) 67.9 (8.6) 0.005 
Age at menopause, mean (SD) 40.8 (3.0) 50.2 (2.5) 56.0 (1.6) <0.001 
Type 2 Diabetes, Yes (%) 54 (13.0) 304 (10.9) 52 (11.6) 0.11 
Age at menarche, mean (SD) 13.4 (1.9) 13.4 (1.7) 13.6 (2.0) 0.216 
Education, No. (%)    <0.001 
 
Primary 97 (23.4) 427 (15.3) 55 (12.2)  
Lower 200 (48.3) 1451 (52.1) 234 (53.2)  
Intermediate 88 (21.3) 622 (22.3) 108 (23.0)  
Higher/university 29 (7.0) 287 (10.3) 52 (11.6)  
Smoking Status, Yes. (%) 119 (28.7) 539 (19.3) 54 (12.0) <0.001 
Alcohol, mean (SD), g/day 8.7 (11.9) 9.5 (12.5) 11.4 (13.6) 0.003 
Physical activity (METhours/week) 81.4 (44.4) 85.3 (50.4) 83.5 (43.7) 0.297 
Hormone therapy, Yes (%) 9 (2.2)  73 (2.6) 9 (2.0)  0.671 
Oral contraceptive use, yes (%) 190 (45.9) 1464 (52.5) 230 (51.2) 0.041 
Number of pregnancies, mean (SD) 2.5 (2.3) 2.3 (1.9) 2.3 (1.8) 0.235 
*Menopause categories are defined as: Early ≤44 years old, Normal 45-54 and Late ≥55years old. 369 
Abbreviations: SD; standard deviation  370 
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Table 2. Hazard Ratios by Transition Among Categories of Age at Menopause.* 
Transition No. Of Cases Person-years Age at Menopause Categories HR† 95% CI HR‡ 95% CI  
 Incident T2D 28 2612  Late 1.00  1.00   
234 21826  Normal 1.22 0.84,1.78 1.14 0.78,1.67  
42 3917  Early 1.89 1.20,2.97 1.69 1.07,2.67  
 
 
No T2D to Death 68 2607  Late 1.00  1.00   
519 19901  Normal 1.16 0.88,1.54 1.13 0.85,1.49  
97 3719  Early 1.49 1.05,2.09 1.42 1.01,2.00  
 T2D to Death 28 664  Late 1.00  1.00   
148 3507  Normal 0.91 0.56,1.48 0.85 0.52,1.39  
44 1043  Early 1.73 0.99,3.00 1.64 0.93,2.88  
Abbreviations: HR, Hazard Ratio; CI, Confidence Interval; T2D, Type 2 Diabetes. 371 
*Age 50 and over at start of follow-up 372 
† Adjusted for age and cohort 373 
‡ Adjusted for age, cohort, smoking, alcohol, education, physical activity, oral contraceptive use, hormone therapy,  374 
age at menarche, number of pregnancies.  375 
  376 
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Figure 2. Life expectancy at 50 years old among women with late, normal and early menopause.  377 
 378 
 379 
 380 
 381 
  382 
 383 
Abbreviations: HR, hazard ratio; LE life expectancy; T2D type 2 diabetes 384 
*Results after adjusted for: age, cohort, education levels, alcohol, smoking, menarche,  HT, physical activity, number of pregnancies and OC use. 385 
**Late menopause group is the reference category. 386 
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Table 3. Differences of age at menopause categories on life expectancy. 389 
 390 
 391 Age at menopause  
categories 
Difference in total 
LE 
Difference in LE 
free of T2D 
Difference in LE 
with T2D 
Years 95% CI Years 95% CI Years 95% CI 
Early vs. Late -3.5 -6.6,-0.8 -4.6 -8.9,-0.9 1.1 -1.8,4.4 
Normal vs. Late -0.5 -2,1,1.3 -1.3 -4.3,0.8 0.8 -1.3,2.4 
Early vs. Normal -3.1 -5.1,-1.1 -3.3 -6.0,-0.6 0.2 -2.0,2.8 
Abbreviations: LE life expectancy; T2D type 2 diabetes, CI confidence interval 
